Pegfilgrastim

Patient w/ sickle cell disease. Not intended for treatment of myelodysplastic syndrome, chronic myelogenous leukaemia and secondary acute myeloid leukaemia (AML). Pregnancy and lactation. Monitoring Parameters Obtain CBC w/ differential and platelet count prior to and during therapy. Monitor haematocrit regularly.

Bone or musculoskeletal pain, hypersensitivity reactions (e.g. urticaria, skin rash, angioedema, erythema, flushing, dyspnoea, hypotension, cutaneous vasculitis, SC tissue disorders), splenomegaly, glomerulonephritis, leukocytosis, pulmonary AR (e.g. interstitial pneumonia; pulmonary oedema, infiltrates and fibrosis).
Potentially Fatal: Splenic rupture, resp failure or acute resp distress syndrome, capillary leak syndrome, serious allergic reactions (e.g. anaphylaxis), sickle cell crises (in patients w/ sickle cell disorders).

Diminished therapeutic effect w/ pegloticase.

Haematopoietic Agents

L03AA13 - pegfilgrastim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.